BHS

Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023

Face to face Meeting

www.bhs.be

BHS Multiple Myeloma study group

Michel Delforge

Marie-Christiane Vekemans

BHS
Belgian Hematology Society

38th General Annual Meeting of
the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

BHS MM active study group members

- Greet Bries
- Géraldine Claes
- Julie Dallemagne
- Julien Depaus
- Bernard De Prijck
- Jo Caers
- Lien Deleu
- Michel Delforge (chair)
- Hilde Demuynck
- Hadewijch De Samblanx
- Anne Deweweire
- Chantal Doyen
- Karel Fostier
- Caroline Jacquy
- Alain Kentos
- Nicolas Kint
- Helena Maes
- Nathalie Meuleman
- Philippe Mineur
- Fritz Offner
- Alexander Salembier
- Rik Schots
- Isabelle Van de Broek
- Jan Van Droogenbroeck
- Ann Van de Velde
- Marie-Christiane Vekemans
- Marie Vercruyssen
- Géraldine Verstraete
- Katrien Voet
- Ka Lung Wu

BHS MM active study group 2022 meetings

- ✓ January 21
- ✓ May 12
- ✓ September 22
- ✓ December 16

Achievement in 2022 : investigator-driven clinical study

COMPASS study

COMParison of different geriAtric Screening methods in newly diagnoSed multiple myeloma patients, and assessment of therapeutic efficacy and toxicity in fit and frail patients.

A multicenter observational Belgian study

Achievement in 2022 : real life data

BELCOMM study

Ciltacabtagene autoleucel for patients with triple-class exposed multiple myeloma: adjusted comparison of CARTITUDE-1 patients outcome versus real-world clinical practice in Belgium

HemaSphere

Articles & Issues | Subject Areas | Featured Content | For Authors | About Us

Outline

Images

Download

Cite

LETTER

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Delforge, Michel[1,*]; Vekemans, Marie-Christiane[2,*]; Depaus, Julien[3]; Meuleman, Nathalie[4]; Van de Velde, Ann[5,6]; Vande Broek, Isabelle[7]; Vandervennet, Sophie[8]; Van Hoorenbeeck, Sandra[8]; Moorkens, Evelien[8]; Strens, Danielle[9]; Diels, Joris[10]; Ghilotti, Francesca[11]; Haefliger, Benjamin[12]; Dalhuisen, Sander[13]; Deraedt, William[10]; Anguille, Sébastien[5,14]

Author Information

HemaSphere 6(12):p e813, December 2022. | *DOI:* 10.1097/HS9.0000000000000813

BHS Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting



Figure 2.: Unadjusted and IPW-ATT adjusted Kaplan-Meier curves, PFS (A), TTNT (B), and OS (C), infused/aligned populations. Unweighted Kaplan-Meier curves in the cilta-cel and RWCP groups for the infused/aligned population are shown for (A) PFS; (B) TTNT; and (C) OS. IPW-ATT adjusted Kaplan-Meier curves for the reweighted RWCP group are also presented. For all endpoints, separation between curves indicative of superior benefits with cilta-cel is apparent. ATT = average treatment effect in the treated population; CI = confidence interval; HR = hazard ratio; IPW = inverse probability weighting; OS = overall survival; PFS = progression-free survival; RWCP = real-world clinical practice; TTNT = time to next treatment.

Achievement in 2022 : clinical trial proposal

DRd fixed versus continuous in newly diagnosed patients



After extensive internal and external discussions with KCE and HOVON: insufficient patients in Belgium to do this trial in 3 years.
Possibility to collaborate with HOVON, if they will do the study…

Achievement in 2022 : clinical trial proposal

Prospective observational study on the clinical efficacy of teclistamab in patients with relapsed and refractory multiple myeloma

Protocol: Teclistamab in R/R MM

Version number: v1.0 – **Date 5/1/2023**

Reimbursement of teclistamab currently pending

Achievement in 2022 : MRD network MMOVE



- MRD assessment in BM is currently primarily performed for MM patients with undetectable paraprotein in serum/urine (biochemical CR)
- Project to provide MRD detection by NGF and NGS for MM patients in Belgium, with financial support from Janssen
- Collect data and use the network and data as leverage for future reimbursement
- Mass spec is in rapid evolution and might set a new standard for MRD in the following years

Financially supported by Janssen

Achievement in 2022 : MRD network MMOVE



Reference centra onboarded

- UZ Leuven (37 samples)
- UZ Brussel (9 samples)
- UZ Gent

Reference centra contract negotiations

- Jessa ziekenhuis
- CHU Namur
- CHU Liège

Referral centra onboarded

- UZ Leuven: AZ Turnhout, Imeldaziekenhuis Bonheiden, Clinique Saint-Pierre Ottignies
- UZ Brussel: OLV Aalst, Algemeen Stedelijk Ziekenhuis Aalst, Sint Maria Halle, AZ Delta, AZ Klina

Financially supported by Janssen

Collaborative group studies



Active participation in both groups remains important

- Succesful participation in the HOVON 141/Cassiopeia – MIDAS - CARISMM
- Representatives in IFM board: Nathalie Meuleman and MC. Vekemans
- Representative in HOVON board: MC. Vekemans

Collaborative group studies

EMN

Representative in EMN board:
Michel Delforge

Treatment guidelines

- Newly diagnosed MM
- First relapse

→ efforts of MC Vekemans

- Late relapses
- AL amyloidosis

→ planned for 2023

Yearly symposium

BHS
Belgian Hematology Society

38th General Annual Meeting of
the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

Multi stakeholder symposium on Amyloidosis

CHAIRS

- **Prof. Dr. Antoine Bondue**, Cardiologist, Hôpital Erasme, Université Libre de Bruxelles
- **Prof. Dr. Kristl Claeys**, Neurologist, UZ Leuven, KU Leuven
- **Prof. Dr. Michel Delforge**, Hematologist, UZ Leuven, KU Leuven
- **Prof. Dr. Anne-Catherine Pouleur**, Cardiologist, Cliniques universitaires Saint-Luc, UC Louvain

BHS
Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

Multi stakeholder symposium on Myeloma

Prof. Landgren: Treatment landscape in R/R MM
19.00 – 19.20h
col15@miami.edu

Share experience in R/R MM, reflect to BE situation

Send slides to Amgen by Aug 26, 2022
Pre-recording Sept 7, 2022 +live Q&A

Prof. Vekemans: challenging clinical case in R/R MM
19.20 – 19.35h
marie-christiane.vekemans@saintluc.uclouvain.be

Share a challenging clinical case and Q&Awith input from Prof. Landgren

Share case(s) with other speakers upfront
Send slides to Amgen by Oct 3, 2022
Live presentation

Prof. Delforge: challenging clinical case in R/R MM
19.35 – 19.50h
michel.delforge@uzleuven.be

Share a challenging clinical case and Q&Awith input from Prof. Landgren

Share case(s) with other speakers upfront
Send slides to Amgen by Oct 3, 2022
Live presentation

19.50 – 20.00h: Q&A discussion

Open discussion to the online audience (all 3 speakers)

AMGEN

BHS Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

Recent changes in drug reimbursement

In first line

In relapse

- Belantamab since January 2022
- Isa-Pd since April 2022



Potential future changes in drug reimbursement in 2023-2024

In first line

? Dara-VTD

In relapse

? Isa-Kd

? Dara-Kd

? Dara-VCD in AL amyloidosis

? Teclistamab

? Talquetamab

? CAR-T

Actions concerning reimbursement in 2022-2023

Letters to the Cabinet of Minister Vandenbroeck

- Reimbursement of serum FLC assay
- Reimbursement of daratumumab in severe AL amyloidosis
  Dara-VCD

Plans for 2023

- Guidelines
- Analysis of the COMPASS data

- Registries
  - EuroCAST initiative on Castelman and Belgian data
  - Teclistamab early access program: experiences, tocilizumab access, data collection

- Seminar in Fall 2023
  - Practical aspects on immunotherapies administration - CAR-T

- New studies

BHS MM course – April 22d, 2023

- MGUS/MGCS and other plasma cell dyscrasias
- MM first line
- MM early relapses
- MM late relapses
- Side effects of MM drugs and MM supportive care
- AL amyloidosis and other deposition diseases